Advanced Targeted Therapies in Cancer

Abstract

Advanced targeted therapies have transformed the landscape of cancer treatment by concentrating on the specific genetic and molecular abnormalities that drive tumor development and progression. Unlike traditional treatments such as chemotherapy and radiotherapy, which often affect both healthy and cancerous cells, targeted therapies act selectively on critical signaling pathways, oncogenes, and tumor-specific biomarkers. This category of treatment includes small-molecule inhibitors, monoclonal antibodies, antibody–drug conjugates, gene therapy approaches, and CAR-T cell therapy, all designed to directly attack cancer cells while minimizing damage to normal tissues. The incorporation of biomarkers and precision medicine has further refined cancer care by enabling treatment strategies tailored to each patient’s unique tumor characteristics. Recent advancements, including liquid biopsy technologies, improved targeted agents, and artificial intelligence–assisted treatment planning, have strengthened the impact of these therapies. However, issues such as drug resistance, tumor heterogeneity, high cost, limited accessibility, and the need for specialized infrastructure continue to pose significant challenges. Despite these limitations, advanced targeted therapies represent a major milestone in oncology, offering improved treatment effectiveness, enhanced quality of life, and a promising future for personalized cancer management.